Last reviewed · How we verify
NCT03428321
Small and Steatotic Hepatocellular Carcinoma
trial in HCC in 238 participants. Completed in 30 December 2019.
1 November 2019
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 238 |
| Start date | 1 January 2015 |
| Primary completion | 1 November 2019 |
| Estimated completion | 30 December 2019 |
| Sites | 1 location across France |
Conditions studied
- HCC — all drugs for HCC →
Sponsor
University Hospital, Montpellier
Who can join
18 and older, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Percutaneous thermoablation in an effective local curative treatment in patients with cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A). Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules. We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC). No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm). This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: Predictive Factors of Recurrence and Survival in Western Patients.
Hermida M, Cassinotto C, Piron L, Aho-Glélé S, et al · · 2020 · cited 27× · PMID 32013112 · DOI 10.3390/cancers12020313 -
Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation.
Hermida M, Preel A, Assenat E, Piron L, et al · · 2021 · cited 9× · PMID 33860126 · DOI 10.1002/hep4.1661 -
Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation.
Preel A, Hermida M, Allimant C, Assenat E, et al · · 2021 · cited 7× · PMID 34070800 · DOI 10.3390/cancers13112700 -
Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation.
Gozzo C, Hermida M, Herrero A, Panaro F, et al · · 2022 · cited 4× · PMID 35932178 · DOI 10.1002/hep4.2063
Verify or expand the search:
- PubMed search for NCT03428321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HCC
Currently open trials in the same condition.
- NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
- NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
- NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
- NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
- NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03428321 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 6 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03428321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing